Panacea Life Sciences Holdings, Inc.
PLSH
$0.0539
$0.005912.29%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.76M | 2.39M | 1.75M | 1.77M | 1.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.76M | 2.39M | 1.75M | 1.77M | 1.84M |
| Cost of Revenue | 6.62M | 6.46M | 6.06M | 6.07M | 6.24M |
| Gross Profit | -3.86M | -4.08M | -4.31M | -4.30M | -4.40M |
| SG&A Expenses | 1.46M | 1.47M | 845.90K | 830.70K | 890.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.08M | 7.93M | 6.90M | 6.90M | 7.13M |
| Operating Income | -5.31M | -5.55M | -5.15M | -5.13M | -5.29M |
| Income Before Tax | -7.67M | -8.02M | -7.51M | -8.05M | -8.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.67 | -8.02 | -7.51 | -8.05 | -8.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.67M | -8.02M | -7.51M | -8.05M | -8.15M |
| EBIT | -5.31M | -5.55M | -5.15M | -5.13M | -5.29M |
| EBITDA | -3.64M | -3.83M | -3.44M | -3.40M | -3.56M |
| EPS Basic | -0.46 | -0.49 | -0.47 | -0.52 | -0.55 |
| Normalized Basic EPS | -0.25 | -0.26 | -0.25 | -0.27 | -0.29 |
| EPS Diluted | -0.46 | -0.49 | -0.47 | -0.52 | -0.55 |
| Normalized Diluted EPS | -0.25 | -0.26 | -0.25 | -0.27 | -0.29 |
| Average Basic Shares Outstanding | 67.41M | 65.89M | 64.09M | 62.33M | 59.65M |
| Average Diluted Shares Outstanding | 67.41M | 65.89M | 64.09M | 62.33M | 59.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
